Avidity Biosciences/$RNA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Avidity Biosciences
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
Ticker
$RNA
Sector
Primary listing
Employees
391
Headquarters
Website
RNA Metrics
BasicAdvanced
$11B
-
-$4.19
0.90
-
Price and volume
Market cap
$11B
Beta
0.9
52-week high
$70.76
52-week low
$21.51
Average daily volume
7.2M
Financial strength
Current ratio
11.573
Quick ratio
11.131
Long term debt to equity
2.439
Total debt to equity
2.649
Profitability
EBITDA (TTM)
-609.062
Gross margin (TTM)
-2,239.41%
Net profit margin (TTM)
-2,634.59%
Operating margin (TTM)
-2,934.90%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
-20.28%
Return on equity (TTM)
-32.44%
Valuation
Price to revenue (TTM)
445.066
Price to book
5.5
Price to tangible book (TTM)
5.5
Price to free cash flow (TTM)
-15.682
Free cash flow yield (TTM)
-6.38%
Free cash flow per share (TTM)
-4.508
Growth
Revenue change (TTM)
106.27%
Earnings per share change (TTM)
46.89%
3-year revenue growth (CAGR)
35.94%
3-year earnings per share growth (CAGR)
8.61%
What the Analysts think about RNA
Analyst ratings (Buy, Hold, Sell) for Avidity Biosciences stock.
Bulls say / Bears say
Novartis agreed to acquire Avidity for $72 per share in cash—a 46% premium to the prior closing price—valuing the company at approximately $12 billion and underscoring strong strategic validation of its AOC platform. (Reuters)
Avidity shares jumped over 43% in premarket trading following the Novartis announcement, reflecting robust investor confidence in the value of its late-stage neuromuscular pipeline. (Reuters)
Reports in August indicated Novartis was actively considering an acquisition of Avidity, driving a 23% share surge and foreshadowing strong M&A interest in Avidity’s RNA therapeutic delivery technology. (Reuters)
Negotiations for Novartis’ takeover of Avidity were reported as preliminary and could fall through or face competing bids, adding uncertainty to the transaction’s completion. (Reuters)
Despite the acquisition hype, analysts remain cautious about Avidity’s AOC platform’s ability to consistently deliver RNA therapeutics to muscle tissue, questioning long-term clinical viability. (Reuters)
Some market observers noted the $72/share all-cash price was significantly higher than Novartis’s usual bolt-on acquisitions, highlighting a risk of overpayment that could pressure returns. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2025.
RNA Financial Performance
Revenues and expenses
RNA Earnings Performance
Company profitability
RNA News
AllArticlesVideos
RNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avidity Biosciences, Inc. Is Fair to Shareholders
Business Wire2 weeks ago
Avidity Biosciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avidity Biosciences, Inc. - RNA
Business Wire2 weeks ago
Avidity Biosciences Soars After $72 Per Share Novartis Takeover
Benzinga2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Avidity Biosciences stock?
Avidity Biosciences (RNA) has a market cap of $11B as of November 13, 2025.
What is the P/E ratio for Avidity Biosciences stock?
The price to earnings (P/E) ratio for Avidity Biosciences (RNA) stock is 0 as of November 13, 2025.
Does Avidity Biosciences stock pay dividends?
No, Avidity Biosciences (RNA) stock does not pay dividends to its shareholders as of November 13, 2025.
When is the next Avidity Biosciences dividend payment date?
Avidity Biosciences (RNA) stock does not pay dividends to its shareholders.
What is the beta indicator for Avidity Biosciences?
Avidity Biosciences (RNA) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.